Zogenix is committed to developing and commercializing therapies for central nervous system disorders that address specific clinical needs for people living with rare diseases and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
We seek best-in-class leaders with scientific, medical and commercial expertise in the therapeutic areas in which we participate. By sharing a collective passion for making a difference in the lives of patients we serve, our unique company culture thrives through the principles of ethical decision making, open communication and collaboration.
Zogenix was founded in 2006 and has offices in California, Japan, and the United Kingdom. Zogenix International, Ltd. is a wholly owned subsidiary of Zogenix.